Two peptides. Dozens of recovery mechanisms. One question researchers keep asking. When the preclinical literature on tissue repair is this dense, choosing between BPC-157 and TB-500 isn't a matter of preference — it requires understanding what each compound actually does at the molecular level, and where the evidence genuinely holds up.
Contents
BPC-157: What the Research Shows
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — 15 amino acids — derived from a protective protein originally isolated from human gastric juice. CAS 137525-51-0. Molecular formula C₆₂H₉₈N₁₆O₂₂.
What makes this compound unusual in the peptide research landscape isn't just its mechanism — it's its stability. BPC-157 is active orally in animal models, which is rare for peptides of this complexity.
Tendon and Ligament Research
The most robustly replicated findings for BPC-157 come from musculoskeletal models. Staresinic et al. (2006, J Orthop Res) demonstrated accelerated medial collateral ligament healing in rats, with histological evidence of improved collagen fibre organisation at 14 and 21 days post-injury compared to controls.
Gastrointestinal Protection
The GI protection literature on BPC-157 is genuinely extensive. Gwyer et al. (2019, Curr Pharm Des) reviewed the evidence in inflammatory bowel disease models and found consistent cytoprotective effects across multiple injury paradigms. The compound has reached Phase II clinical trials under the designation PL 14736 for inflammatory bowel disease.
VEGF Upregulation and Angiogenesis
BPC-157 consistently upregulates vascular endothelial growth factor (VEGF) in wound healing models. This pro-angiogenic activity is one reason why the compound shows effects across such diverse tissue types — vascular supply is rate-limiting for healing in many contexts.
TB-500: What the Research Shows

TB-500, as used in research contexts, typically refers to thymosin beta-4 (Tβ4) — a 43-amino acid, 4,963 Da peptide originally isolated from the thymus but found in virtually every nucleated cell in the body. Unlike BPC-157, thymosin beta-4 has genuine endogenous biology.
The Actin Connection
The primary mechanism of Tβ4 is actin sequestration. The peptide binds monomeric G-actin with high affinity, effectively buffering the intracellular pool of free actin and regulating the dynamics of actin polymerisation. Cell migration — the fundamental process by which repair cells move to injury sites — is entirely actin-dependent.
Cardiac and Vascular Research
The cardiac data on TB-500 is among the most striking in the entire peptide research field. Bock-Marquette et al. (2004, Nature) demonstrated that Tβ4 activates cardiac progenitor cells, promoting cardiomyocyte differentiation and survival after ischaemic injury. The compound was shown to activate integrin-linked kinase (ILK), leading to Akt phosphorylation and downstream cell survival signalling.
Ac-SDKP: The Active Fragment
A significant portion of Tβ4's anti-inflammatory activity is mediated by a tetrapeptide fragment released during its degradation: Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline). This fragment acts as an endogenous inhibitor of haematopoietic stem cell differentiation and has anti-fibrotic properties.
Mechanisms Head-to-Head
The most important thing to understand about BPC-157 vs TB-500 is that they work through genuinely different pathways.
BPC-157 acts primarily through:
- Nitric oxide (NO) system modulation
- VEGF upregulation → neovascularisation at injury sites
- FAK/paxillin pathway activation → fibroblast migration and matrix organisation
- Growth hormone receptor interaction
TB-500 acts primarily through:
- G-actin sequestration → regulated cytoskeletal dynamics
- Integrin-linked kinase (ILK) activation → Akt survival signalling
- Cell migration enhancement — keratinocytes, fibroblasts, progenitor cells
- Anti-inflammatory via Ac-SDKP metabolite → reduced fibrosis
Reconstitution & Handling in Research Contexts
BPC-157 is notably more stable than most peptides of comparable complexity. In its lyophilised form, it maintains integrity at −20°C for extended periods. Once reconstituted in bacteriostatic water, it should be stored at 2–8°C and used within 28–30 days.
TB-500 is a larger, more complex molecule and requires more careful handling. It is sensitive to repeated freeze-thaw cycles — each cycle degrades peptide integrity measurably. For research use, aliquoting into single-use volumes before freezing is standard practice. Once reconstituted, TB-500 should be used within 5–7 days when stored at 4°C.
Stack Research: Do BPC-157 and TB-500 Work Together?
Given that BPC-157 and TB-500 act through distinct, non-competing pathways, the theoretical basis for studying them in combination is sound. The literature doesn't yet contain substantial head-to-head stack studies — most research has examined the compounds individually — but the mechanistic case for complementarity is clear.
BPC-157's primary contributions (NO modulation, VEGF-driven vascular supply, FAK-mediated fibroblast function) address different rate-limiting steps in tissue repair than TB-500's contributions (actin-dependent cell migration, progenitor cell recruitment, ILK/Akt survival signalling).
Research FAQ
What is the core structural difference between BPC-157 and TB-500?
BPC-157 is a 15-amino acid synthetic pentadecapeptide (MW 1,419.56 Da) derived from a protein in human gastric juice with no natural equivalent. TB-500 is the synthetic form of thymosin beta-4 (Tβ4), a 43-amino acid, ~4,963 Da protein that is naturally abundant in virtually every nucleated cell in the body.
Do BPC-157 and TB-500 work through the same mechanisms?
No — the primary mechanisms are distinct. BPC-157 acts principally through the nitric oxide system, VEGF upregulation, and FAK/paxillin pathway activation. TB-500 acts primarily through G-actin sequestration and integrin-linked kinase (ILK) activation. Both produce downstream pro-angiogenic and pro-reparative effects, but via non-overlapping upstream signals.
Which compound has stronger evidence in the published literature?
Both have substantial bodies of preclinical evidence, but the nature of that evidence differs. BPC-157 has 400+ PubMed citations, largely from one prolific research group (Sikiric at Zagreb). TB-500's cardiac data (Bock-Marquette et al., Nature 2004) represents arguably the most rigorously replicated finding for either compound, with multiple independent labs confirming key results. TB-500 is also further along in clinical translation.
Are BPC-157 and TB-500 approved for human use?
Neither BPC-157 nor TB-500 is approved for human use by any regulatory authority (EMA, FDA, or equivalent) as of 2026. Both compounds are supplied by UNIK LAB exclusively for in vitro research and laboratory use.
What is Ac-SDKP and how does it relate to TB-500 research?
Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is a tetrapeptide released during the enzymatic degradation of thymosin beta-4. It has well-documented anti-fibrotic properties — demonstrated in renal, cardiac, and pulmonary fibrosis models. TB-500 research potentially involves two bioactive species: the intact Tβ4 molecule driving pro-repair activity, and the Ac-SDKP metabolite providing anti-fibrotic counterbalance.
Available from UNIK LAB
BPC-157 10mg€39
Research-grade BPC-157 10mg · HPLC verified ≥98% · COA included · 48h EU/UK dispatch
